Safety and Efficacy of Biweekly Gemcitabine in Combination with Capecitabine in Elderly and Frail Patients with Resected Pancreatic Cancer
DOI:
https://doi.org/10.17140/POJ-6-119Keywords:
Gemcitabine; Capecitabine; Pancreatic cancer.Abstract
Background The European Study Group for Pancreatic Cancer (ESPAC-4) study showed that gemcitabine and capecitabine (GemCap) con-ferred a survival benefit over gemcitabine monotherapy in resected pancreatic cancer (PC) patients. ESPAC-4 included patients with a median age of 65-years (37-81) and Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0,1 in 97%. We present our experience with an adopted biweekly regimen of GemCap in patients who were ≥75-years old and deemed not suitable for the ESPAC-4 regimen. MethodsPatients received a biweekly regimen of GemCap (gemcitabine 1000 mg/m2 every 2-weeks and capecitabine 1000 mg/m2 twice a day orally on days 1-7 every 2-weeks). Patients were evaluated for progression-free survival (PFS), overall survival (OS), and sites of recurrence. Toxicities were graded according to National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) v5.0.ResultsThirty-five (35) patients with a median age of 79-years were treated with biweekly GemCap adjuvant treatment. Seventy-two percent (72%) of patients had ECOG PS of 2. The median PFS and OS were 8-months and 22-months. Twenty-five percent (25%) had local recurrence, 60% had metastatic disease and 8.6% had no evidence of disease (NED). The most frequent toxici-ties were grades 1-2 anemia (20%), thrombocytopenia (8%), and hand-foot syndrome (HFS) (10%). Grade ≥3 included diarrhea (4%) and HFS (1%). Conclusion Our study showed that biweekly gemcitabine in combination with capecitabine can be an acceptable regimen with efficacy com-parable to historical control and a favorable toxicity profile in elderly and frail patients. Patients on this regimen also make fewer visits to the oncologist. A biweekly GemCap regimen warrants further exploration in patients not suitable for FOLFIRINOX (a combination of bolus and infusional fluorouracil, leucovorin, irinotecan and oxaliplatin), full-dose GemCap, or a clinical trial.
References
Kleeff J, Korc M, Apte M, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016; 2: 16022. doi: 10.1038/nrdp.2016.22
Liao WC, Chien KL, Lin YL, et al. Adjuvant treatments for resec-ted pancreatic adenocarcinoma: A systematic review and network meta-analysis. Lancet Oncol. 2013; 14: 10951-1103. doi: 10.1016/ S1470-2045(13)70388-7
Daoud V, Saif MW, Goodman M. Adjuvant treatment for pancreatic cancer. JOP. 2014; 15: 348-350. doi: 10.6092/1590- 8577/2692
Birkmeyer JD, Finlayson SR, Tosteson AN, Sharp SM, Warshaw AL, Fisher ES. Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy. Surgery. 1999; 125(3): 250-256. doi: 10.1016/S0039-6060(99)70234-5
Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant com-bined radiation and chemotherapy following curative resec-tion. Arch Surg. 1985; 120(8): 899-903. doi: 10.1001/arch-surg.1985.01390320023003
Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiothe-rapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999; 230(6): 776-782; discussion 782-784. doi: 10.1097/00000658- 199912000-00006
Neoptolemos JP, Dunn JA, Moffitt DD, et al. for the members of the European Study Group for Pancreatic Cancer (ESPAC). ESPAC-1: A European, randomized controlled study of adjuvant chemoradiation and chemotherapy in resectable pancreatic cancer. Lancet. 2001; 358: 1576-1585. doi: 10.1016/s0140-6736(01)06651-x
Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gem-citabine chemotherapy before and after fluorouracil-based che-moradiation following resection of pancreatic adenocarcinoma: A Retrospective Study | Volume 6 | Number 1 | Saif MW, et al randomized controlled trial. JAMA. 2008; 299(9): 1019-1026. doi: 10.1001/jama.299.9.1019
Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA. 2007; 297(3): 267-277. doi: 10.1001/jama.297.3.267
Neoptolemos JP, Stocken DD, Bassi C, et al. European Stu-dy Group for Pancreatic Cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: A randomized controlled trial. JAMA. 2010; 304: 1073-1081. doi: 10.1001/jama.2010.1275
Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine mo-notherapy in patients with resected pancreatic cancer (ESPAC-4): A multicentre, open-label, randomised, phase 3 trial. Lancet. 2017; 389(10073): 1011-1024. doi: 10.1016/S0140-6736(16)32409-6
Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: A phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016; 388(10041): 248-257. doi: 10.1016/S0140-6736(16)30583-9
Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gem-citabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018; 379(25): 2395-2406. doi: 10.1056/NEJMoa1809775
Scheithauer W, Schull B, Ulrich-Pur H, et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: A randomized phase II trial. Ann Oncol. 2003; 14: 97-104. doi: 10.1093/annonc/mdg029
Scheithauer W, Kornek GV, Raderer M, et al. Randomized mul-ticenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2003; 21(7): 1307-1312. doi: 10.1200/JCO.2003.09.016
Bryson E, Sakach E, Patel U, et al. Safety and efficacy of 7 days on/7 days off versus 14 days on/7 days off schedules of capecita-bine in patients with metastatic colorectal cancer: A retrospective review. Clin Colorectal Cancer. 2021; 20(2): 153-160. doi: 10.1016/j. clcc.2020.12.002
Common Terminology Criteria for Adverse Events (CTCAE). Website. https://ctep.cancer.gov/protocoldevelopment/electro-nic_applications/docs/ctcae_v5_quick_reference_5x7.pdf. Publi-shed November 27, 2017. Accessed September 29, 2023.
Aapro M, Schwenkglenks M, Lyman GH, et al. Pegfilgras-tim primary prophylaxis vs. current practice neutropenia mana-gement in elderly breast cancer patients receiving chemotherapy. Crit Rev Oncol Hematol. 2010; 74: 203-210. doi: 10.1016/j.critre-vonc.2009.06.004
Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: A 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004; 22: 4626-4631. doi: 10.1200/JCO.2004.02.175
Higuera O, Ghanem I, Nasimi R, et al. Management of pancrea-tic cancer in the elderly. World J Gastroenterol. 2016; 22: 764-775. doi: Submit your article to this journal | https://openventio.org/submit-manuscript/ 10.3748/wjg.v22.i2.764
Bauer MR, Bright EE, MacDonald JJ, Cleary EH, Hines OJ, Stanton AL. Quality of life in patients with pancreatic cancer and their caregivers: A systematic review. Pancreas. 2018; 47: 368-375. doi: 10.1097/MPA.0000000000001025
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Pancreas (POJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
